Psilocybin Advisory Board Research Subcommittee Meeting
The Oregon Psilocybin Advisory Board Research Subcommittee held a meeting on April 28, 2021, to discuss topics such as the benefits and harms of psilocybin in controlled settings, key questions for research, and inviting guest speakers. The meeting agenda included a guest speaker session by Dr. Roger Chou and discussions on finalizing the evidence review process and structure.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
Oregon Psilocybin Advisory Board Research Subcommittee Research Subcommittee Meeting Meeting April 28, 2021 Members: Todd Korthuis (co-chair) Atheir Abbas (co-chair) Tom Jeanne Ali Hamada Jessie Uehling Tom Jeanne Christopher Stauffer Angela Carter
Agenda Agenda 1. Guest speaker: Dr. Roger Chou, Director, Pacific Northwest Evidence-Based Practice Center (10-15 min) 2. Subcommittee discussion on finalizing process/structure for evidence review (35 min) - Review roles - Review timeline - Approve Key Questions 3. Subcommittee process for inviting guest speakers? (10 min)
Key Questions Key Questions 1. What are the benefits and harms* of psilocybin in controlled setting in persons seeking treatment for improving condition-specific symptoms and quality of life for: a. Depression b. Anxiety disorders c. Trauma-related disorders, including racial trauma d. Alcohol use disorder e. Tobacco use disorder f. Other drug use disorders g. Palliative care h. Other conditions 2. What are the benefits and harms* of psilocybin for personal use? KQ 1 & 2 Subquestions: Subquestion: How do the benefits and harms of psilocybin differ by population subgroups? Subquestion: How do the benefits and harms of psilocybin differ by dosing strategy? Subquestion: What are best practices for dose control? 3. What are provider or patient risk assessment tools that can identifying persons likely to benefit or be harmed by psilocybin-assisted therapy? 4. What are the relative benefits and harms of specific sources of psilocybin sources including mushrooms? *includes interpersonal, medical, and psychological harms
Proposed Gant Chart Proposed Gant Chart (Thank you, Dr. Uehling!)
